Intermediate Risk Rhabdomyosarcoma in Very Young Children (Less Than or Equal to 24 Months) Treated on the Prior Children's Oncology Group Protocol ARST1431
Pediatric Blood & Cancer · 2026-06 · 73 (6)
DOI: 10.1002/1545-5017.70293 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 31.03.2026. Verfasst von Katrina Winsnes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Oregon Health and Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: St. Baldrick's Foundation, Summer's Way Foundation, NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Rhabdomyosarcoma is the most common soft tissue sarcoma in pediatrics and infants are reported to have inferior outcomes. ARST1431 recommended delayed primary excision (DPE) while discouraging radiation (RT) deviations. This analysis compared outcomes among very young and older patients in this study. Procedures Demographic and tumor characteristics were summarized using frequencies and percentages. Local failure (LF) frequency was summarized by age group, RT, and DPE status. Event‐free survival (EFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared between age groups using the log‐rank test.
Results
Of 296 patients, 48 (16.2%) were
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Oregon Health and Science University, Portland, Oregon, USA.
- Department of Radiation Oncology, University of Florida, Jacksonville, Florida, USA.
- Department of Biostatistics, College of Public Health and Health Professions College of Medicine, University of Florida, Gainesville, Florida, USA.
- Division of Hematology/Oncology, Sickkids, University of Toronto, Ontario, Canada.
- Department of Pediatric General and Thoracic Surgery, Seattle Children's Hospital, Seattle, Washington, USA.
- Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.
ORCID-Profile: Katrina Winsnes
Förderung
- St. Baldrick's Foundation
- Summer's Way Foundation
- NIH HHS
- NCTN Statistics & Data Center
- NCI NIH HHS
- Friends of TJ Foundation
- Maddie's Promise Foundation
- Sebastian Strong Foundation
Zitieren
APA
Winsnes, K., Bradley, J. A., Gao, Z., Gupta, A. A., Rothstein, D. H., Shenoy, A., Venkatramani, R., Xue, W., & Arndt, C. (2026). Intermediate Risk Rhabdomyosarcoma in Very Young Children (Less Than or Equal to 24 Months) Treated on the Prior Children's Oncology Group Protocol ARST1431. Pediatric Blood & Cancer, 73(6). https://doi.org/10.1002/1545-5017.70293
Vancouver
Winsnes K, Bradley JA, Gao Z, Gupta AA, Rothstein DH, Shenoy A, et al. Intermediate Risk Rhabdomyosarcoma in Very Young Children (Less Than or Equal to 24 Months) Treated on the Prior Children's Oncology Group Protocol ARST1431. Pediatric Blood & Cancer. 2026;73(6). doi:10.1002/1545-5017.70293
BibTeX
@article{Winsnes2026,
author = {Winsnes, Katrina and Bradley, Julie A and Gao, Zhengya and Gupta, Abha A and Rothstein, David H and Shenoy, Archana and Venkatramani, Rajkumar and Xue, Wei and Arndt, Carola},
title = {Intermediate Risk Rhabdomyosarcoma in Very Young Children (Less Than or Equal to 24 Months) Treated on the Prior Children's Oncology Group Protocol ARST1431},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {6},
doi = {10.1002/1545-5017.70293}
}
EUVIMED